[
    [
        {
            "time": "2021-09-30",
            "original_text": "复星医药：同意以15.961亿元的对价转让复星医药出售权益",
            "features": {
                "keywords": [
                    "复星医药",
                    "转让",
                    "亚能生物",
                    "金石医检所",
                    "股权"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：同意以15.961亿元的对价转让复星医药出售权益",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药拟转让亚能生物及金石医检所股权 预计贡献收益约14亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "亚能生物",
                    "金石医检所",
                    "股权转让",
                    "收益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药拟转让亚能生物及金石医检所股权 预计贡献收益约14亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药(02196)拟15.961亿元向康桥五期美元基金出售亚能生物29.02%股权及金石医检所100%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "康桥五期美元基金",
                    "亚能生物",
                    "金石医检所",
                    "股权转让"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)拟15.961亿元向康桥五期美元基金出售亚能生物29.02%股权及金石医检所100%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药(02196.HK)拟为控股子公司复星实业提供不超1亿美元担保 大额借贷担保",
            "features": {
                "keywords": [
                    "复星医药",
                    "复星实业",
                    "担保",
                    "借贷"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)拟为控股子公司复星实业提供不超1亿美元担保 大额借贷担保",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药：拟转让亚能生物及金石医检所股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "亚能生物",
                    "金石医检所",
                    "股权转让"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：拟转让亚能生物及金石医检所股权",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药(600196.SH)：集团拟以15.96亿元转让亚能生物29.02%股权及金石医检所100%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "亚能生物",
                    "金石医检所",
                    "股权转让"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：集团拟以15.96亿元转让亚能生物29.02%股权及金石医检所100%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药(600196.SH)：子公司联合注射用曲妥珠单抗联合化疗(XELOX)启动II期临床研究",
            "features": {
                "keywords": [
                    "复星医药",
                    "曲妥珠单抗",
                    "化疗",
                    "临床研究"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：子公司联合注射用曲妥珠单抗联合化疗(XELOX)启动II期临床研究",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-09-30",
            "original_text": "复星医药：拟转让所持亚能生物合计29.02%股权及金石医检所100%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "亚能生物",
                    "金石医检所",
                    "股权转让"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：拟转让所持亚能生物合计29.02%股权及金石医检所100%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]